In the 1990s, the first clinical IVR systems (Interactive Voice Response Systems) were developed in order to randomise patients over the phone, and later, to dispense drug and resupply sites as well.
The life sciences location of Austria has gained considerable momentum since the founding of the very first Austrian biotech company Intercell at the turn of the millennium. Today the whos who of the biotech sector relies on Austria, in particular on its capital city of Vienna.
The development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy
https://european-biotechnology.com/wp-content/uploads/2024/05/EB122_Editorial_Michael-Brandkamp_tg-scaled.jpg17072560Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2022-03-22 10:24:002024-07-18 14:24:29The Next Big Thing: “Biologisation”
The development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy
https://european-biotechnology.com/wp-content/uploads/2024/05/EB122_Editorial_Michael-Brandkamp_tg-scaled.jpg17072560Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2022-03-22 10:24:002024-07-18 14:24:29The Next Big Thing: "Biologisation"
https://european-biotechnology.com/wp-content/uploads/2024/04/Cibusrtds-beyond-plants-yeast.png400435Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-03-20 15:34:002024-04-04 16:47:24Switzerland paves the way for genome editing
Gilde Healthcare Private Equity IV (GHPE IV) has closed at €517m for investments in proifitable healthcare companies in the lower mid-market in North-west Europe.
https://european-biotechnology.com/wp-content/uploads/2024/04/Geldbaum-pixabay.com_kalhh.jpg9341280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-03-16 08:01:192024-04-04 16:47:26Precirix NV raises €80m in Series B financing
Saxony has established itself as a dynamic life-sciences hub and provides an attractive environment for investors and start-ups The SaxoCell network and CMI major research centre are furthering innovations in cell and gene therapy Interdisciplinary co-operation offers huge growth opportunities for applications such as point-of-care diagnostics Leipzig as host of BIO-Europe 2022
https://european-biotechnology.com/wp-content/uploads/2024/04/Life-sciences_hub_Saxony.jpeg10801920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-03-15 16:00:002024-04-02 15:34:52Life-sciences hub Saxony: a driver of innovation for cell and gene therapy
RTSM benefits: configuration versus customisation
BackgroundIn the 1990s, the first clinical IVR systems (Interactive Voice Response Systems) were developed in order to randomise patients over the phone, and later, to dispense drug and resupply sites as well.
Austria magnet for biotechnology
Sponsored PublicationsThe life sciences location of Austria has gained considerable momentum since the founding of the very first Austrian biotech company Intercell at the turn of the millennium. Today the whos who of the biotech sector relies on Austria, in particular on its capital city of Vienna.
The Next Big Thing: “Biologisation”
OpinionThe development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy
The Next Big Thing: "Biologisation"
OpinionThe development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy
Switzerland paves the way for genome editing
Latest NewsSwitzerland is keeping its moratorium on GMO cultivation until 2025, but paving the way for exceptions in precision breeding.
Gilde Healthcare Private Equity IV launches €517m
Latest NewsGilde Healthcare Private Equity IV (GHPE IV) has closed at €517m for investments in proifitable healthcare companies in the lower mid-market in North-west Europe.
Precirix NV raises €80m in Series B financing
Latest NewsWith €80m from a Series B financing in its pocket, Belgian Precirix NV plans to advance its pipeline of precision radiopharmaceuticals.
Sanofi bags €300m from US investor Blackstone
Latest NewsSanofi has secured money from Blackstone Life Sciences to speed up development of its daratumumab competitor isatuximab in multiple myeloma.
Life-sciences hub Saxony: a driver of innovation for cell and gene therapy
Sponsored PublicationsSaxony has established itself as a dynamic life-sciences hub and provides an attractive environment for investors and start-ups The SaxoCell network and CMI major research centre are furthering innovations in cell and gene therapy Interdisciplinary co-operation offers huge growth opportunities for applications such as point-of-care diagnostics Leipzig as host of BIO-Europe 2022
Join 900 US CEOs protest against Ukraine invasion
Latest NewsUS Life Science leaders pledge to economically disengage from Russia.